Scynexis (SCYX) Income from Non-Controlling Interests (2014)
Scynexis' (SCYX) quarterly Income from Non-Controlling Interests came in at -$7.3 million in Q2 2014, down 162.2% on a QoQ basis from -$2.8 million in Q1 2014.
Scynexis (SCYX) Income from Non-Controlling Interests (2014) Analysis & Trends
Scynexis (SCYX) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$7.3 million in Q2 2014.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$7.3 million in Q2 2014, while the trailing twelve-month figure through Mar 2015 was -$7.3 million (changed N/A YoY) and the FY2014 annual result came in at -$10.1 million, changed N/A from the prior year.
- Income from Non-Controlling Interests declined to -$7.3 million in Q2 2014, from -$2.8 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$2.8 million in Q1 2014 to a low of -$7.3 million in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Scynexis | 60.95 Mn | -53.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | -7.30 Mn |
| Mar 31, 2014 | -2.78 Mn |